Phase 2 IMscin002 Study Shows Patients With NSCLC Prefer Sub

Patients with non–small cell lung cancer treated on the IMscin002 trial preferred subcutaneous atezolizumab vs the intravenous formulation.

Related Keywords

Italy , Federico Cappuzzo , Eli Lilly , European Lung Cancer Congress , Pfizer , European Commission , Bristol Myers Squibb , Illumina Inc , Mirati Therapeutics Inc , Bayer Ag , Roche Ltd , Astrazeneca , Takeda Pharmaceuticals , Amgen Inc , Lung Cancer , Medical Oncology , Azienda Unit , Sanitaria Locale , Mirati Therapeutics , Galecto Biotech , Imscin002 , Nsclc , Non Small Cell Lung Cancer , Atezolizumab , Tecentriq , Subcutaneous Atezolizumab , Intravenous Atezolizumab , Phase 2 Imscin002 Trial , Felcc , D , Enhanze , Azienda Unità Sanitaria Locale Della Romagna Ravenna ,